Clinical Trial Detail

NCT ID NCT04344795
Title Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics
Indications

colorectal cancer

Advanced Solid Tumor

urinary bladder cancer

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

stomach cancer

Therapies

TPST-1495

Pembrolizumab + TPST-1495

Age Groups: adult senior

No variant requirements are available.